Segall Bryant & Hamill’s VanEck Biotech ETF BBH Stock Holding History

Segall Bryant & Hamill’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,340	Closed	-$833K	–	527
2023 Q2	$833K	Buy	5,340 +250	+5%	+$39.9K	0.01%	507
2023 Q1	$825K	Sell	5,090 -1,000	-16%	-$162K	0.01%	514
2022 Q4	$972K	Hold	6,090	–	–	0.01%	491
2022 Q3	$857K	Hold	6,090	–	–	0.01%	509
2022 Q2	$889K	Sell	6,090 -300	-5%	-$44.7K	0.01%	510
2022 Q1	$1.04M	Buy	+6,390	New	+$1.03M	0.01%	513
2021 Q4	–	Sell	-5,140	Closed	-$1.04M	–	607
2021 Q3	$1.04M	Hold	5,140	–	–	0.01%	525
2021 Q2	$1.04M	Hold	5,140	–	–	0.01%	517
2021 Q1	$902K	Hold	5,140	–	–	0.01%	566
2020 Q4	$873K	Buy	5,140 +50	+1%	+$8.24K	0.01%	490
2020 Q3	$826K	Buy	5,090 +1,500	+42%	+$244K	0.01%	479
2020 Q2	$585K	Sell	3,590 -1,650	-31%	-$251K	0.01%	555
2020 Q1	$670K	Hold	5,240	–	–	0.01%	526
2019 Q4	$731K	Hold	5,240	–	–	0.01%	589
2019 Q3	$617K	Hold	5,240	–	–	0.01%	615
2019 Q2	$675K	Sell	5,240 -200	-4%	-$24.7K	0.01%	617
2019 Q1	$699K	Hold	5,440	–	–	0.01%	604
2018 Q4	$602K	Buy	5,440 +200	+4%	+$24.2K	0.01%	615
2018 Q3	$713K	Hold	5,240	–	–	0.01%	612
2018 Q2	$629K	Buy	5,240 +500	+11%	+$58.9K	0.01%	621
2018 Q1	$570K	Buy	4,740 +240	+5%	+$30.1K	0.01%	415
2017 Q4	$561K	Buy	4,500 +200	+5%	+$25.5K	0.01%	403
2017 Q3	$577K	Hold	4,300	–	–	0.01%	404
2017 Q2	$540K	Buy	4,300 +1,050	+32%	+$127K	0.01%	418
2017 Q1	$387K	Buy	3,250 +700	+27%	+$81.9K	0.01%	445
2016 Q4	$274K	Hold	2,550	–	–	0.01%	483
2016 Q3	$294K	Hold	2,550	–	–	0.01%	477
2016 Q2	$261K	Buy	+2,550	New	+$272K	0.01%	493
2015 Q3	–	Sell	-1,500	Closed	-$202K	–	547
2015 Q2	$202K	Buy	+1,500	New	+$199K	﹤0.01%	533

Other funds holding BBH

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CIG

Consolidated Investment Group Englewood, Colorado $1.15B AUM 55.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Segall Bryant & Hamill's BBH Position: Q3 2023 in Review

Segall Bryant & Hamill sold out of VanEck Biotech ETF (BBH) in Q3 2023, closing a stake of 5,340 shares — an estimated $833K sold.

Segall Bryant & Hamill first reported a position in BBH in Q2 2015 and held it in 29 quarters. The position peaked at $1.04M in Q3 2021. 110 funds tracked by Wall St. Rank hold BBH as of Q3 2023.

Segall Bryant & Hamill reported no remaining VanEck Biotech ETF position as of Q3 2023 after selling out during the quarter.
Segall Bryant & Hamill sold 5,340 VanEck Biotech ETF shares in Q3 2023, an estimated $833K.
Segall Bryant & Hamill first reported a position in VanEck Biotech ETF in Q2 2015 and held it in 29 quarters.
Segall Bryant & Hamill's VanEck Biotech ETF position peaked at $1.04M in Q3 2021.
110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q3 2023.

Based on Segall Bryant & Hamill's 13F filing for Q3 2023, filed 9 Nov 2023.